Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR)
Primary Purpose
Postprandial Hyperglycemia, Metabolic Disorder, Glucose
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
High fat low carbohydrate diet
Low fat high carbohydrate diet
Sponsored by
About this trial
This is an interventional prevention trial for Postprandial Hyperglycemia focused on measuring Personalized Nutrition, Glucose Metabolism, Gut Microbiota
Eligibility Criteria
Inclusion Criteria:
- Willingness and capability to complete the study protocol
Exclusion Criteria:
- Inability or unwillingness to approved to provide informed consent
- Neurological conditions that might affect the assessment of the study measurement
- Hospitalization or surgery planned within 3 months
- Gastrointestinal diseases
- Other serious medical conditions, such as liver, kidney, or systemic disease
- Women who are pregnant or lactating
- Tobacco, alcohol, or illicit drug abuse
- Had taken antibiotics in the past two weeks prior to the start of the trial
- Participants on a vegan diet
- Any food allergy
- Lack of smart phone and data plan for participating caregiver
- Non-Chinese speaking participants
- Participating in another concurrent intervention study
Sites / Locations
- Westlake University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
High fat low carbohydrate diet
Low fat high carbohydrate diet
Arm Description
Outcomes
Primary Outcome Measures
Postprandial blood glucose change
Postprandial blood glucose from different foods will be assessed.
Blood glucose profiling
Glucose levels will be recorded by continuous glucose monitoring over the intervention periods.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04125602
Brief Title
Westlake N-of-1 Trials for Macronutrient Intake
Acronym
WE-MACNUTR
Official Title
Westlake Personalized Nutrition Intervention Study: N-of-1 Trials for Dietary Macronutrient Intake
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
October 20, 2019 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Westlake University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a dietary intervention study in students and staff of Westlake University, which is designed to provide evidence in support of N-of-1 methods as an approach to advance personalized nutrition. The primary aim is using a series of N-of-1 trials to determine the impacts of a high fat, low carbohydrate diet (HF-LC) on glucose metabolism and gut microbiota in subjects versus a low fat, high carbohydrate diet (LF-HC) at both the individual and group level.
Detailed Description
This study will employ a series of individual N-of-1 trials comparing a high fat, low carbohydrate diet (HF-LC) to a low fat, high carbohydrate diet (LF-HC). Participants will enter the study on a usual diet and will have a 6-day run in period for diet planning and baseline data collection before beginning their intervention. The HF-LC or the LF-HC will be randomized as the starting intervention followed by a wash-out period lasting for 6 days with normal diet between two interventions to eliminate previous intervention effects. Then the participants will be provided with the other diet. Both HF-LC and LF-HC last for 6 days in each set which consists of two wash-out periods and two intervention periods. There will be 3 sets in this study and investigators will aggregate the results of the completed N-of-1 trials across all participants to estimate the group level impacts of HF-LC compared to LF-HC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postprandial Hyperglycemia, Metabolic Disorder, Glucose
Keywords
Personalized Nutrition, Glucose Metabolism, Gut Microbiota
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High fat low carbohydrate diet
Arm Type
Experimental
Arm Title
Low fat high carbohydrate diet
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
High fat low carbohydrate diet
Other Intervention Name(s)
HF-LCD
Intervention Description
Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
Intervention Type
Other
Intervention Name(s)
Low fat high carbohydrate diet
Other Intervention Name(s)
LF-HCD
Intervention Description
Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
Primary Outcome Measure Information:
Title
Postprandial blood glucose change
Description
Postprandial blood glucose from different foods will be assessed.
Time Frame
Day 7-12 and day 19-24 of each set
Title
Blood glucose profiling
Description
Glucose levels will be recorded by continuous glucose monitoring over the intervention periods.
Time Frame
Day 7-12 and day 19-24 of each set
Other Pre-specified Outcome Measures:
Title
Fecal metabolites
Description
Fecal metabolite extracts will be analysed by performing liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/Q-TOF/MS).
Time Frame
Day 1, day7, day 13 and day 19 of each set
Title
Fecal microbiota
Description
Gut microbial communities and their abundant features will be analysed based on shotgun metagenomic sequencing.
Time Frame
Day 1, day7, day 13 and day 19 of each set
Title
Metabolomics profiling
Description
Targeted metabonomics are analyzed based on urine and faeces at all visits (also based on serum in set 1).
Time Frame
Day 1, day7, day 13 and day 19 of each set
Title
Laboratory markers of glucose metabolism and inflammation
Description
insulin, leptin, adiponection, free fatty acid, Interleukin(IL)-6, IL-8, IL-10, IL-12, IL-17A, IL-1ra, tumour necrosis factor alpha (TNF-α), Lipopolysaccharide binding protein (LBP), cortisol, high-sensitivity C-reactive protein, serum amyloid A, soluble E-selectine, soluble intracellular adhesion molecule-1, plasminogen activator inhibitor-1, vascular cell adhesion molecule, monocyte chemoattractant protein (MCP)-1, adrenaline, noradrenaline, peptide YY, and neuropeptide Y are tested at all visits of set 1.
Time Frame
Day 1, day7, day 13 and day 19 of set 1
Title
Lipid metabolism
Description
Triglyceride, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B are tested at all visits of set 1.
Time Frame
Day 1, day7, day 13 and day 19 of set 1
Title
Physiological characteristics
Description
Weight and blood pressure are collected at all visits of set 3.
Time Frame
Day 1, day7, day 13 and day 19 of set 3
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Willingness and capability to complete the study protocol
Exclusion Criteria:
Inability or unwillingness to approved to provide informed consent
Neurological conditions that might affect the assessment of the study measurement
Hospitalization or surgery planned within 3 months
Gastrointestinal diseases
Other serious medical conditions, such as liver, kidney, or systemic disease
Women who are pregnant or lactating
Tobacco, alcohol, or illicit drug abuse
Had taken antibiotics in the past two weeks prior to the start of the trial
Participants on a vegan diet
Any food allergy
Lack of smart phone and data plan for participating caregiver
Non-Chinese speaking participants
Participating in another concurrent intervention study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ju-Sheng Zheng, PhD
Organizational Affiliation
Westlake University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Westlake University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310024
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32968703
Citation
Tian Y, Ma Y, Fu Y, Zheng JS. Application of n-of-1 Clinical Trials in Personalized Nutrition Research: A Trial Protocol for Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR). Curr Dev Nutr. 2020 Aug 26;4(9):nzaa143. doi: 10.1093/cdn/nzaa143. eCollection 2020 Sep.
Results Reference
derived
Learn more about this trial
Westlake N-of-1 Trials for Macronutrient Intake
We'll reach out to this number within 24 hrs